



Financial report 2021 – 2022

2021

Revenues 2021




Expenditures 2021




2022

Revenues 2022



Expenditures 2022



Comments to the financial report 2021

Revenues

The revenues for 2021 don't differ much from what had been expected during the AGM.

The income of the CAB was a bit higher than foreseen, the income from the CF Round Table of companies a bit lower.

Expenditures

Research – EU projects

Both EU projects faced challenges in 2021.

Due to COVID both projects got delayed.

OligoG struggled with preparation of the recruitment.

HIT-CF was confronted with the volatile pharmaceutical sector, where companies discontinued their participation or merged with other companies. This resulted in more delays.

CFE is responsible for dissemination in this project, and depends on the project moving forward to be able to disseminate information and result. That is why the expenditures for the EU-projects are lower than expected in 2021.

Care

Also in 2021 the annual conference took place online.

We decided not to organize the South Eastern European conference didn't take place. Networking is an important part of this conference and not possible when it is online.

This is why the budget spent on care was limited in 2021.

Comments to the financial report 2022

Revenues

CAB

Starting from 2022 the CAB has been out-sourced to Eupati – Spain. They took over the logistics and administration of the CAB. That means the payment for the CAB goes to them and CFE receives only a fee from EUPATI Spain for the work CFE does on the CAB.

CFRToC

The consolidation of memberships of the CF Round Table of Companies proved to be challenging in 2022.

Emergency fund to Ukraine

The situation in Ukraine was unforeseen and unprecedented.

CFE, set up a fundraising exercise to help the people with CF from and in Ukraine. These funds came from member organisations, individuals and companies. In kind help is not included in this graph but was also a very important resource for us to be able to help

Expenditures

Research – EU projects

Also in 2022 both EU projects faced challenges.

The OligoG project was stopped before the end of the project.

The HIT-CF project faced further delay in the start of the clinical study.

CFE is responsible for dissemination in this project, and depends on the project moving forward to be able to disseminate information and result. That is why the expenditures for the EU-projects are lower than expected, also in 2022.

Care

The budget spent on care in 2022 is considerably higher than in 2021.

The annual meeting could take place in Rotterdam.

CFE supported a regional conference in Eastern Europe

Emergency fund to Ukraine

The difference between the revenues and expenditures on Ukraine are a result of staff costs not being included in the expenditures. CFE received a grant, especially to be able to pay someone of the team to work on this issue.

Financial costs

In January 2022 the OligoG-project informed us that they would stop the project because recruitment didn't seem feasible.

We had counted on the project to continue and the grant to come in this year. That didn't happen, and therefore there is a financial cost of €29 250.

This results in a negative total result for 2022 that was not foreseeable.